CMV Infection Impacts Health Related Quality of Life After Solid Organ Transplantation

Sommer, W.; Simon, Andrè; Warnecke, G.; Schwarz, Arne Kristian; Barg‐Hock, Hannelore; Weißenborn, Karin; Bara, Christoph; Gottlieb, Jens; Haverich, Axel; Kugler, C

doi:10.1097/00007890-201007272-01406

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Post-transplant CMV infection is associated with considerable healthcare resource utilization and costs [ 9 ]. Studies have also shown that post-transplant CMV infection has a detrimental impact on the health-related quality of life (HRQoL) of allogeneic HSCT [ 10 ] and SOT [ 11 ] recipients. Further, many health technology assessments agencies, including the National Institute for Health and Care Excellence (NICE) in the UK, require health-related utility data to inform economic evaluations of treatments and to calculate quality adjusted life years [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

“…The use of vignettes is recommended as an alternative by NICE when EQ-5D data are either unsuitable or unavailable [ 16 ]. CMV can have diverse and complex impacts on the HRQoL of post-transplant patients [ 10 , 11 ], and EQ-5D-5L data captured during the SOLISTICE trial may not have adequately captured all of the relevant effects on patient HRQoL of R/R CMV, its complications, and its treatment. Therefore, there were limited EQ-5D data available for all the health states required for the cost-effectivenes model.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A time trade-off study to determine health-state utilities of transplant recipients with refractory cytomegalovirus infection with or without resistance

Ahmed,

Longworth,

Oluboyede

et al. 2024

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background Health-state utility values (HSUVs) for post-transplant refractory cytomegalovirus (CMV) infection (with or without resistance [R/R]) were determined using a time trade-off (TTO) survey completed by 1,020 members of the UK general public. Methods Existing literature and qualitative interviews with clinicians experienced in treating R/R CMV were used to develop initial draft vignettes of health states. The vignettes were refined to describe three clinical states of R/R CMV: clinically significant and symptomatic (CS-symptomatic CMV); clinically significant and asymptomatic (CS-asymptomatic CMV); and non-clinically significant (non-CS CMV). Each clinical state was valued independently and combined with three events of interest: graft-versus-host disease; kidney graft loss; and lung graft loss to generate twelve vignettes. The final vignettes were evaluated by a sample of the UK general public using an online TTO survey. Exclusion criteria were applied to the final data to ensure that responses included in the analysis met pre-defined quality control criteria. Results Overall, 738 participants met the inclusion criteria and were included in the analysis. The sample was representative of the UK general population in terms of age and sex. Non-CS CMV had the highest mean HSUV (95% confidence interval) (0.815 [0.791, 0.839]), followed by CS-asymptomatic CMV (0.635 [0.602, 0.669]), and CS-symptomatic CMV (0.443 [0.404, 0.482]). CS-symptomatic CMV with lung graft loss had the lowest mean HSUV (0.289), with none of the health states considered on average worse than dead. Conclusions Post transplant R/R CMV has substantial impact on the health-related quality of life of patients. The utility values obtained in this study may be used to support economic evaluations of therapies for R/R CMV infection.

show abstract